Analysis
Bottazzi and her co-developer, Peter Hotez, explicitly rejected patenting Corbevax to prioritize global accessibility, sharing the vaccine’s production protocol via **Texas Children’s Hospital Center for Vaccine Development** and publishing details in peer-reviewed journals (e.g., *Vaccines*, 2022). Their actions align with the stated moral obligation, as the vaccine was designed for low-cost manufacturing (under $2/dose) and licensed to producers in **India, Indonesia, Botswana, and Bangladesh** without royalties. The *Nature* interview (June 2022) and subsequent public statements confirm this intent. No evidence contradicts the claim’s core assertion about open-sharing or ethical motivation.
Background
Corbevax, a recombinant protein vaccine for COVID-19, was developed at **Baylor College of Medicine** with funding from philanthropic and U.S. government sources (e.g., NIH). Unlike mRNA vaccines, its traditional technology enables easier technology transfer to low-resource settings. Bottazzi and Hotez have consistently advocated for **patent-free vaccines** as a tool for pandemic equity, criticizing pharmaceutical monopolies in interviews and op-eds (*The Guardian*, 2021; *Science*, 2022).
Verdict summary
Maria Elena Bottazzi accurately described the open-release of Corbevax’s patent-free, protein-subunit technology and her team’s ethical stance on equitable vaccine access.